Sovateltide (PMZ-1620), an Endothelin-B receptor Agonist, has the potential to be a first-in-class neuronal progenitor cell therapeutics

Monday, September 30, 2019 Genetics & Stem Cells News
Email Print This Page Comment bookmark
Font : A-A+

WILLOWBROOK, Ill., Sept. 30, 2019 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced that it made 5 presentations at the Sixteenth International Conference on Endothelin held in Kobe, Japan from September

22nd to 25th, 2019. Keynote lecture titled "Sovateltide (IRL-1620): A neuronal progenitor cell therapeutics" was presented by Dr. Anil Gulati, Chairman and CEO of Pharmazz, Inc. Other abstracts presented at the meeting are:

Sovateltide (PMZ-1620) for cerebral ischemic stroke. Abstract titled "Randomized, double-blind, saline-controlled, multicenter clinical study to determine efficacy of sovateltide (PMZ-1620) in patients with cerebral ischemic stroke." Authors: Anil Gulati, Nilesh Radheshyam Agrawal, Deepti Vibha, U.K. Misra, Birinder Singh Paul, Rajnish Kumar, Jeyaraj Pandian, and Manish S Lavhale. Pharmazz has completed human phase II trial (NCT04046484; CTRI/2017/11/010654) and has initiated a randomized, multicenter phase III study (NCT04047563; CTRI/2019/09/021373). Clinical phase II results indicate that PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that promotes statistically significant quicker recovery and improves neurological outcome in acute cerebral ischemic stroke patients.

Sovateltide (PMZ-1620) for Alzheimer's disease. Abstract titled "Neurorestorative potential of sovateltide (IRL-1620) by promoting neurogenesis and synaptogenesis in APP/PS1 transgenic mouse model of Alzheimer's disease." Authors: Seema Briyal, Ralf Voshtina, and Anil Gulati. Human phase II trial is in progress and 49 patients with Alzheimer's disease have been enrolled till date (NCT04052737; CTRI/2017/12/016394). Interim results will be available in about a month.

Sovateltide (PMZ-1620) for acute spinal cord injury. Abstract titled "Administration of sovateltide (IRL-1620), the most powerful endothelin-B receptor agonist, significantly improves motor recovery and activates neurogenic pathways in animal model of spinal cord injury." Authors: Michele Fornaro, Harsh Sharthiya, Seema Briyal, and Anil Gulati. Clinical phase II study is in progress and 10 patients with acute spinal cord injury (NCT04054414; CTRI/2018/12/016667) has been enrolled.

Sovateltide (PMZ-1620) for cerebral ischemic stroke. Abstract titled "Sovateltide (IRL-1620) enhances mitochondrial biogenesis and neural regeneration in ischemic brain." Authors: Amaresh Ranjan, Seema Briyal, and Anil Gulati.

PMZ-1620 (IRL-1620; INN sovateltide) has the potential to be a first-in-class neuronal progenitor cell therapeutics with anti-apoptotic activity that improves cerebral blood flow and neurological outcome in cerebral ischemic stroke patients.

About Pharmazz, Inc. Pharmazz, Inc. is a privately-held company engaged in the development of novel products in the area of critical care medicine. Additional information may be found on the Company's website, www.pharmazz.com.  

Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties including the risk that Pharmazz, Inc. cannot execute its business plan for lack of capital or other resources, distribution, partnering or licensing/acquisition opportunities. Actual events or results may differ materially from those projected in any of such statements due to various factors. Any of these risks could cause Pharmazz, Inc. or its industry's, actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements in this presentation. Except as required by applicable law Pharmazz, Inc. does not intend to update any of the forward-looking statements to conform these statements to actual results.

ContactPharmazz, Inc.   Shruti Gulati630-780-6087shruti.gulati@pharmazz.com 

 

Cision View original content:http://www.prnewswire.com/news-releases/sovateltide-pmz-1620-an-endothelin-b-receptor-agonist-has-the-potential-to-be-a-first-in-class-neuronal-progenitor-cell-therapeutics-300927491.html

SOURCE Pharmazz, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store